Association between induced organ atrophy assessed by artificial intelligence-generated automatic segmentation and efficacy of bevacizumab in combination with chemotherapy in metastatic colorectal cancer.

Fiche publication

Date publication

novembre 2025

Journal

Cancer imaging : the official publication of the International Cancer Imaging Society

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Pr HOEFFEL Christine , Pr LEPAGE Côme

Tous les auteurs :
Laich M, Brugel M, Conze PH, Abbas M, Abdelghanie MB, Khemissa F, Kircher S, Le Malicot K, Lepage C, Aparicio T, Hoeffel C, Bouché O, Carlier C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41214758

Résumé

Bevacizumab, an angiogenesis inhibitor, is commonly used alongside chemotherapy for metastatic colorectal cancer (mCCR). While inducing necrosis in tumours, bevacizumab may also lead to atrophy in tumour-free organs. Artificial intelligence (AI) models offer user-friendly methods for measuring organ volumes. This study explores the relationship between bevacizumab-induced atrophy using AI-assisted volume measurement in tumour-free organs and treatment efficacy.